Comparison of ASAS and BASDAI Scores before and after 12 weeks of treatment
| Response measure: assessment point | Placebo (n = 39) | Etanercept (n = 45) | p Value* |
|---|---|---|---|
| *Differences in mean percentage change, baseline to week 12, by the Cochrane-Mantel-Haenszel test. | |||
| ASAS, Assessments in Ankylosing Spondylitis; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. | |||
| ASAS: Spinal inflammation | |||
| Baseline (mean) | 62.9 | 67.5 | |
| Week 12 (% change) | 52.6 (15.9) | 35.6 (43.3) | 0.003 |
| ASAS: Nocturnal and total pain | |||
| Baseline (mean) | 56.1 | 60.0 | |
| Week 12 (% change) | 51.2 (6.2) | 31.0 (43.1) | 0.000 |
| ASAS: Patient global assessment | |||
| Baseline (mean) | 63.4 | 65.6 | |
| Week 12 (% change) | 54.1 (12.6) | 38.4 (37.0) | 0.011 |
| ASAS: Functional impairment (BASFI) | |||
| Baseline (mean) | 57.2 | 60.2 | |
| Week 12 (% change) | 53.9 (3.4) | 39.6 (35.4) | 0.000 |
| BASDAI: Composite score | |||
| Baseline (mean) | 58.6 | 61.0 | |
| Week 12 (% change) | 50.1 (13.6) | 33.8 (43.6) | 0.001 |
| BASDAI: Fatigue score | |||
| Baseline (mean) | 59.0 | 68.2 | |
| Week 12 (% change) | 54.8 (−4.9) | 38.4 (42.6) | 0.000 |